A Phase 1 interventional study of Carfilzomib in Relapsed Multiple Myeloma and End-stage Renal Disease, sponsored by Amgen. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.
Sponsored by Amgen · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 86th largest by enrollment, is one of 10 that started in 2014, is one of 17 in phase 1, and was the 40th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 33rd largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2014, is one of 13 in phase 1, and was the 24th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with normal kidney function and those with end-stage renal disease to see if they respond differently to the study drug.
Specifically, the purpose of this study is to assess the influence of end-stage renal disease (ESRD) on area under the curve (both area under the curve, from time 0 to the last concentration measured [AUC0-last] and area under the curve, from time 0 extrapolated to infinity [AUC0-inf]) of carfilzomib 56 mg/m² at Cycle 2 Day 1 (C2D1) in patients with relapsed multiple myeloma.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with normal renal function (creatinine clearance \[CrCl\] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
Drug: Carfilzomib
Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
Drug: Carfilzomib
Carfilzomib was administered by IV injection.
Also known as: Kyprolis®
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Carfilzomib plasma concentrations for pharmacokinetic (PK) analyses were measured by liquid chromatography with tandem mass spectrometry. The lower limit of quantitation (LLOQ) for the assay was 0.3 ng/mL.
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2
Time frame: Cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1
Time frame: Cycle 1, day 16 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-389/M14
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Maximum Observed Plasma Concentration for Metabolite PR-389/M14
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-389/M14
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life (T½) of Metabolite PR-389/M14
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-413/M15
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-413/M15
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-413/M15
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-413/M15
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life (T½) of Metabolite PR-413/M15
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-519/M16
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) for Metabolite PR-519/M16
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Maximum Observed Plasma Concentration (Cmax) for Metabolite PR-519/M16
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Observed Plasma Concentration (Tmax) for Metabolite PR-519/M16
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Terminal Half-life (T½) of Metabolite PR-519/M16
Time frame: Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.
Number of Participants With Adverse Events (AEs)
Determination of the severity of all adverse events was assessed following the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Fatal. A Serious AE is an AE that meets one or more of the following criteria: * Death, * Life-threatening experience; * Requires in-patient hospitalization or prolongation of an existing hospitalization, * Results in persistent or significant disability/incapacity, * Is a congenital anomaly/birth defect, * Important medical events that may not result in death, be life-threatening, or require hospitalization. Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship.
Time frame: From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 12 October 2015; median duration of treatment was 14 weeks in the normal renal function group and 12 weeks in the ESRD group.
Participants were enrolled at 13 investigative study centers (6 in the United States, 2 in Canada, and 5 in Australia) from 29 January 2014 to 25 March 2015. This study is ongoing, results are reported as of the data cut-off date of 12 October 2015.
| Milestone | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Started | 15 | 11 |
| Completed | 12 | 8 |
| Not completed | 3 | 3 |
| Withdrew: On-study at the data cut-off date | 3 | 3 |
Carfilzomib plasma concentrations for pharmacokinetic (PK) analyses were measured by liquid chromatography with tandem mass spectrometry. The lower limit of quantitation (LLOQ) for the assay was 0.3 ng/mL.
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 563 ± 41.9 | 747 ± 143.9 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 563 ± 41.8 | 752 ± 144.7 |
| ng/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 1389 ± 26.8 | 1567 ± 128.8 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 0.467 (0.250 to 0.733) | 0.467 (0.250 to 0.583) |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Terminal Half-life (T½) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 0.341 (0.111 to 0.498) | 1.25 (0.0632 to 3.31) |
| liters/hour | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Clearance (CL) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 179 ± 38.9 | 134 ± 136.9 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Mean Residence Time (MRT) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 0.135 ± 62.6 | 0.245 ± 79.9 |
| liters | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Volume of Distribution at Steady State (Vss) of Carfilzomib Following 56 mg/m² Carfilzomib on Day 1 of Cycle 2 | 24.1 ± 44.8 | 32.8 ± 133.9 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 344 ± 24.8 | 480 ± 36.0 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 347 ± 26.3 | 479 ± 46.6 |
| ng/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 819 ± 29.8 | 1022 ± 37.2 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 0.583 (0.467 to 0.733) | 0.467 (0.233 to 0.750) |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Terminal Half-life (T½) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 0.387 (0.0938 to 0.599) | 0.992 (0.918 to 16.0) |
| liters/hour | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Clearance (CL) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 146 ± 23.0 | 93 ± 56.8 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Mean Residence Time (MRT) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 0.222 ± 16.6 | 0.426 ± 152.2 |
| liters | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Volume of Distribution at Steady State (Vss) of Carfilzomib Following 27 mg/m² Carfilzomib on Day 16 of Cycle 1 | 32.0 ± 29.7 | 53.0 ± 185.5 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 320 ± 32.8 | 1486 ± 32.3 |
| Cycle 2, Day 1 (n = 10, 8) | 584 ± 17.5 | 2086 ± 132.8 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 | 355 ± 25.1 | — |
| Cycle 2, Day 1 | 650 ± 22.5 | — |
| ng/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 153 ± 25.4 | 413 ± 32.9 |
| Cycle 2, Day 1 (n = 10, 8) | 302 ± 16.5 | 595 ± 128.4 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 1.00 (0.750 to 1.13) | 1.50 (1.00 to 2.67) |
| Cycle 2, Day 1 (n = 10, 8) | 0.983 (0.583 to 1.02) | 2.00 (1.45 to 4.47) |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 | 1.46 (0.975 to 1.73) | — |
| Cycle 2, Day 1 | 1.10 (0.903 to 1.70) | — |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 33.4 ± 53.9 | 54.6 ± 45.0 |
| Cycle 2, Day 1 (n = 10, 8) | 60.3 ± 48.4 | 86.3 ± 199.1 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 7) | 36.2 ± 54.1 | 66.4 ± 48.7 |
| Cycle 2, Day 1 (n = 10, 5) | 63.8 ± 48.0 | 131 ± 35.8 |
| ng/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 20.7 ± 43.5 | 25.9 ± 42.5 |
| Cycle 2, Day 1 (n = 10, 8) | 40.2 ± 38.5 | 42.3 ± 163.9 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 0.833 (0.683 to 1.00) | 0.767 (0.733 to 1.05) |
| Cycle 2, Day 1 (n = 10, 8) | 0.667 (0.250 to 1.00) | 0.750 (0.717 to 1.52) |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 7) | 1.07 (0.544 to 1.33) | 1.41 (1.30 to 1.86) |
| Cycle 2, Day 1 (n = 10, 5) | 0.962 (0.802 to 1.21) | 1.37 (1.04 to 1.44) |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 82.8 ± 53.1 | 86.8 ± 44.3 |
| Cycle 2, Day 1 (n = 10, 8) | 147 ± 52.8 | 138 ± 126.6 |
| ng*h/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 84.4 ± 52.4 | 89.6 ± 42.8 |
| Cycle 2, Day 1 (n = 10, 8) | 148 ± 51.7 | 139 ± 125.1 |
| ng/mL | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 93.4 ± 40.2 | 90.4 ± 48.0 |
| Cycle 2, Day 1 (n = 10, 8) | 180 ± 40.5 | 151 ± 129.7 |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 0.617 (0.467 to 1.00) | 0.600 (0.467 to 0.917) |
| Cycle 2, Day 1 (n = 10, 8) | 0.525 (0.250 to 0.617) | 0.533 (0.467 to 0.750) |
| hours | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Cycle 1, Day 16 (n = 13, 9) | 0.705 (0.473 to 0.993) | 0.721 (0.518 to 1.42) |
| Cycle 2, Day 1 (n = 10, 8) | 0.617 (0.555 to 0.673) | 0.687 (0.473 to 0.933) |
Determination of the severity of all adverse events was assessed following the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03, where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Fatal. A Serious AE is an AE that meets one or more of the following criteria: * Death, * Life-threatening experience; * Requires in-patient hospitalization or prolongation of an existing hospitalization, * Results in persistent or significant disability/incapacity, * Is a congenital anomaly/birth defect, * Important medical events that may not result in death, be life-threatening, or require hospitalization. Treatment-related adverse events (TRAEs) are adverse events considered related to carfilzomib by the investigator, including those with unknown relationship.
| participants | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| Any adverse event | 15 | 11 |
| Adverse event ≥ Grade 3 | 12 | 9 |
| Serious adverse event | 10 | 9 |
| AE leading to discontinuation of carfilzomib | 6 | 0 |
| Fatal adverse events | 2 | 1 |
| Treatment-related adverse events | 12 | 8 |
| Treatment-related adverse event ≥ Grade 3 | 7 | 6 |
| Serious treatment-related adverse event | 5 | 2 |
| TRAE leading to discontinuation of carfilzomib | 4 | 0 |
| Treatment-related fatal adverse events | 0 | 0 |
Collected over From the first dose of study drug up to 30 days after the last dose of study drug as of the data cut-off date of 12 October 2015; median duration of treatment was 14 weeks in the normal renal function group and 12 weeks in the ESRD group.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Normal Renal Function | — | 10/15 (66.7%) | 14/15 (93.3%) |
| End Stage Renal Disease | — | 9/11 (81.8%) | 10/11 (90.9%) |
| Event | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| PneumoniaInfections and infestations | 3/15 | 2/11 |
| AnaemiaBlood and lymphatic system disorders | 0/15 | 2/11 |
| AstheniaGeneral disorders | 0/15 | 2/11 |
| PyrexiaGeneral disorders | 2/15 | 2/11 |
| Lower respiratory tract infectionInfections and infestations | 1/15 | 2/11 |
| HypotensionVascular disorders | 0/15 | 2/11 |
| Acute kidney injuryRenal and urinary disorders | 2/15 | 0/11 |
| CoagulopathyBlood and lymphatic system disorders | 0/15 | 1/11 |
| Immune thrombocytopenic purpuraBlood and lymphatic system disorders | 0/15 | 1/11 |
| LeukocytosisBlood and lymphatic system disorders | 0/15 | 1/11 |
| Event | Normal Renal Function | End Stage Renal Disease |
|---|---|---|
| NauseaGastrointestinal disorders | 10/15 | 6/11 |
| AnaemiaBlood and lymphatic system disorders | 8/15 | 5/11 |
| FatigueGeneral disorders | 8/15 | 5/11 |
| PyrexiaGeneral disorders | 8/15 | 2/11 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/15 | 1/11 |
| DiarrhoeaGastrointestinal disorders | 7/15 | 5/11 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/15 | 1/11 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/15 | 3/11 |
| ConstipationGastrointestinal disorders | 2/15 | 4/11 |
| VomitingGastrointestinal disorders | 3/15 | 4/11 |
| Age, Continuous(years) | Normal Renal Function | End Stage Renal Disease | Total |
|---|---|---|---|
| Mean | 64.8 ± 8.1 | 62.8 ± 7.9 | 64.0 ± 7.9 |
| Sex: Female, Male(Participants) | Normal Renal Function | End Stage Renal Disease | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 10 | 5 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Normal Renal Function | End Stage Renal Disease | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 14 | 9 | 23 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race/Ethnicity, Customized(participants) | Normal Renal Function | End Stage Renal Disease | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black | 1 | 1 | 2 |
| White | 12 | 9 | 21 |
| Other | 1 | 0 | 1 |
| Not Reported | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Normal Renal Function | End Stage Renal Disease | Total |
|---|---|---|---|
| 0 (Fully active) | 5 | 3 | 8 |
| 1 (Restrictive but ambulatory) | 10 | 7 | 17 |
| 2 (Ambulatory but unable to work) | 0 | 1 | 1 |
The record gives a start of Jan 2014, a primary completion of Apr 2015 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib